A Phase II exploratory study of Ipilimumab N01 in combination with Sintilimab and platinum-based chemotherapy as first-line treatment for locally advanced or metastatic NSCLC with SMARCA4 mutation or deficiency, or STK11/KEAP1 mutations (ChiCTR) - Sep 16, 2026 - P2 | N=64 | Not yet recruiting | Sponsor: Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital); Cancer Hospital of Shandong First Medical U
New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • BRAF • EGFR • HER-2 • KEAP1 • MET • ROS1 • STK11
|